The biological and diagnostic roles of MicroRNAs in meningiomas

References

Adams, L.C., Böker, S.M., Bender, Y.Y., Fallenberg, E.M., Wagner, M., Buchert, R., Hamm, B., and Makowski, M.R. (2017). Assessment of intracranial meningioma-associated calcifications using susceptibility-weighted MRI. Int. J. Magn. Reson. Imag. 46: 1177–1186, https://doi.org/10.1002/jmri.25614.Search in Google Scholar

Akao, Y., Iio, A., Itoh, T., Noguchi, S., Itoh, Y., Ohtsuki, Y., and Naoe, T. (2011). Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol. Ther. 19: 395–399, https://doi.org/10.1038/mt.2010.254.Search in Google Scholar

Azeemuddin, M., Nizamani, W.M., Tariq, M.U., and Wasay, M. (2018). Role of ADC values and ratios of MRI scan in differentiating typical from atypical/anaplastic meningiomas. J. Pak. Med. Assoc. 68: 1403–1406.Search in Google Scholar

Bano, S., Waraich, M.M., Khan, M.A., Buzdar, S.A., and Manzur, S. (2013). Diagnostic value of apparent diffusion coefficient for the accurate assessment and differentiation of intracranial meningiomas. Acta Radiol Short Rep 2, https://doi.org/10.1177/2047981613512484.Search in Google Scholar

Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297, https://doi.org/10.1016/s0092-8674(04)00045-5.Search in Google Scholar

Bica-Pop, C., Cojocneanu-Petric, R., Magdo, L., Raduly, L., Gulei, D., and Berindan-Neagoe, I. (2018). Overview upon miR-21 in lung cancer: focus on NSCLC. Cell. Mol. Life Sci. 75: 3539–3551, https://doi.org/10.1007/s00018-018-2877-x.Search in Google Scholar PubMed

Boetto, J., Bielle, F., Sanson, M., Peyre, M., and Kalamarides, M. (2017). SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro. Oncol. 19: 345–351.10.1093/neuonc/now276Search in Google Scholar

Brastianos, P.K., Horowitz, P.M., Santagata, S., Jones, R.T., McKenna, A., Getz, G., Ligon, K.L., Palescandolo, E., Van Hummelen, P, Ducar, M.D., et al. (2013). Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat. Genet. 45: 285–289, https://doi.org/10.1038/ng.2526.Search in Google Scholar PubMed PubMed Central

Buerki, R.A., Horbinski, C.M., Kruser, T., Horowitz, P.M., James, C.D., and Lukas, R.V. (2018). An overview of meningiomas. Future. Oncol. 14: 2161–2177, https://doi.org/10.2217/fon-2018-0006.Search in Google Scholar PubMed PubMed Central

Chen, K.S., Stroup, E.K., Budhipramono, A., Rakheja, D., Nichols-Vinueza, D., Xu, L., Stuart, S.H., Shukla, A.A., Fraire, C., Mendell, J.T., et al. (2018). Mutations in microRNA processing genes in Wilms tumors derepress the IGF2 regulator PLAG1. Genes. Dev. 32: 996–1007, https://doi.org/10.1101/gad.313783.118.Search in Google Scholar PubMed PubMed Central

Cimino, P.J. (2015). Malignant progression to anaplastic meningioma: neuropathology, molecular pathology, and experimental models. Exp. Mol. Pathol. 99: 354–359, https://doi.org/10.1016/j.yexmp.2015.08.007.Search in Google Scholar PubMed

Clark, V.E., Erson-Omay, E.Z., Serin, A., Yin, J., Cotney, J., Ozduman, K., Avşar, T., Li, J., Murray, P.B., Henegariu, O., et al. (2013). Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339: 1077–1080, https://doi.org/10.1126/science.1233009.Search in Google Scholar PubMed PubMed Central

Clark, V.E., Harmancı, A.S., Bai, H., Youngblood, M.W., Lee, T.I., Baranoski, J.F., Ercan-Sencicek, A.G., Abraham, B.J., Weintraub, A.S., Hnisz, D., et al. (2016). Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat. Genet. 48: 1253–1259, https://doi.org/10.1038/ng.3651.Search in Google Scholar PubMed PubMed Central

Cohen-Inbar, O. (2019). Geriatric brain tumor management part I: meningioma. J. Clin. Neurosci. 67: 5–9, https://doi.org/10.1016/j.jocn.2019.05.063.Search in Google Scholar PubMed

de Almeida, AN, BJA, P., Pires, A.P.H., Paiva, W.S., Cabrera, H.N., da, S.C.C., Teixeira, M.J., and SKN, M. (2017). Clinical outcome, tumor recurrence, and causes of death: a long-term follow-up of surgically treated meningiomas. World. Neurosurg. 102: 139–143, https://doi.org/10.1016/j.wneu.2017.03.009.Search in Google Scholar PubMed

Dirks, M.S., Butman, J.A., Kim, H.J., Wu, T., Morgan, K., Tran, A.P., Lonser, R.R., and Asthagiri, A.R. (2012). Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J. Neurosurg. 117: 109–117, https://doi.org/10.3171/2012.3.jns111649.Search in Google Scholar PubMed PubMed Central

El-Gewely, M.R., Andreassen, M., Walquist, M., Ursvik, A., Knutsen, E., Nystad, M., Coucheron, D.H., Myrmel, K.S., Hennig, R., and Johansen, S.D. (2016). Differentially expressed micrornas in meningiomas grades i and ii suggest shared biomarkers with malignant tumors. Cancers (Basel) 8, https://doi.org/10.3390/cancers8030031.Search in Google Scholar PubMed PubMed Central

Galani, V., Alexiou, G.A., Miliaras, G., Dimitriadis, E., Triantafyllou, E., Galani, A., Goussia, A., Kanavaros, P., and Trangas, T. (2015). Expression of stem cell marker nestin and microrna-21 in meningiomas. Turk. Neurosurg. 25: 574–577.10.5137/1019-5149.JTN.10800-14.2Search in Google Scholar PubMed

Galani, V., Lampri, E., Varouktsi, A., Alexiou, G., Mitselou, A., and Kyritsis, A.P. (2017). Genetic and epigenetic alterations in meningiomas. Clin. Neurol. Neurosurg. 158: 119–125, https://doi.org/10.1016/j.clineuro.2017.05.002.Search in Google Scholar PubMed

Goutagny, S., Bah, A.B., Henin, D., Parfait, B., Grayeli, A.B., Sterkers, O., and Kalamarides, M. (2012). Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro. Oncol. 14: 1090–1096, https://doi.org/10.1093/neuonc/nos129.Search in Google Scholar PubMed PubMed Central

Goutagny, S. and Kalamarides, M. (2010). Meningiomas and neurofibromatosis. J. Neurooncol. 99: 341–347, https://doi.org/10.1007/s11060-010-0339-x.Search in Google Scholar PubMed

Hart, M., Walch-Rückheim, B., Krammes, L., Kehl, T., Rheinheimer, S., Tänzer, T., Glombitza, B., Sester, M., Lenhof, H.P., Keller, A., et al. (2019). miR-34a as hub of T cell regulation networks. J. Immunother. Cancer. 7: 187, https://doi.org/10.1186/s40425-019-0670-5.Search in Google Scholar PubMed PubMed Central

He, M., Gao, L., Zhang, S., Tao, L., Wang, J., Yang, J., and Zhu, M. (2014). Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL. Gastric. Cancer. 17: 431–441, https://doi.org/10.1007/s10120-013-0313-3.Search in Google Scholar PubMed

Hu, S.A., Wei, W., Yuan, J., and Cheng, J. (2019). Resveratrol inhibits proliferation in HBL-52 meningioma cells. Onco. Targets. Ther. 12: 11579–11586, https://doi.org/10.2147/ott.s228513.Search in Google Scholar

Ito, K., Imagama, S., Ando, K., Kobayashi, K., Shido, Y., Go, Y., Arima, H., Kanbara, S., Hirose, T., Matsuyama, Y., et al. (2017). Intraspinal meningioma with malignant transformation and distant metastasis. Nagoya J. Med. Sci. 79: 97–102.Search in Google Scholar

Jiang, B.H. and Liu, L.Z. (2008). PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim. Biophys. Acta. 1784: 150–158, https://doi.org/10.1016/j.bbapap.2007.09.008.Search in Google Scholar PubMed

Jungwirth, G., Warta, R., Beynon, C., Sahm, F., von, D.A., Unterberg, A., Herold-Mende, C., and Jungk, C. (2019). Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Acta Neuropathol. Commun. 7: 140, https://doi.org/10.1186/s40478-019-0793-4.Search in Google Scholar PubMed PubMed Central

Katar, S., Baran, O., Evran, S., Cevik, S., Akkaya, E., Baran, G., Antar, V., Hanimoglu, H., and Kaynar, M.Y. (2017). Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma. Clin. Neurol. Neurosurg. 156: 66–70, https://doi.org/10.1016/j.clineuro.2017.03.016.Search in Google Scholar PubMed

Kliese, N., Gobrecht, P., Pachow, D., Andrae, N., Wilisch-Neumann, A., Kirches, E., Riek-Burchardt, M., Angenstein, F., Reifenberger, G., Riemenschneider, M.J., et al. (2013). miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene 32: 4712–4720, https://doi.org/10.1038/onc.2012.468.Search in Google Scholar PubMed

KMM, A. and Garcia, R.L. (2019). MicroRNA-92a promotes cell proliferation, migration and survival by directly targeting the tumor suppressor gene NF2 in colorectal and lung cancer cells. Oncol. Rep. 41: 2103–2116.Search in Google Scholar

Kopkova, A., Sana, J., Fadrus, P., and Slaby, O. (2018). Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors. Clin. Chem. Lab. Med. 56: 869–879, https://doi.org/10.1515/cclm-2017-0958.Search in Google Scholar PubMed

Kopkova, A., Sana, J., Machackova, T., Vecera, M., Radova, L., Trachtova, K., Vybihal, V., Smrcka, M., Kazda, T., Slaby, O., et al. (2019). Cerebrospinal fluid microrna signatures as diagnostic biomarkers in brain tumors. Cancers (Basel) 11, https://doi.org/10.3390/cancers11101546.Search in Google Scholar PubMed PubMed Central

Kotecha, R.S., Junckerstorff, R.C., Lee, S., Cole, C.H., and Gottardo, N.G. (2011). Pediatric meningioma: current approaches and future direction. J. Neurooncol. 104: 1–10, https://doi.org/10.1007/s11060-010-0503-3.Search in Google Scholar PubMed

Koutsaki, M., Libra, M., Spandidos, D.A., and Zaravinos, A. (2017). The miR-200 family in ovarian cancer. Oncotarget 8: 66629–66640, https://doi.org/10.18632/oncotarget.18343.Search in Google Scholar PubMed PubMed Central

Lan, F., Qing, Q., Pan, Q., Hu, M., Yu, H., and Yue, X. (2018). Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell. Oncol. (Dordr) 41: 25–33, https://doi.org/10.1007/s13402-017-0355-3.Search in Google Scholar PubMed

Lee, H., Hwang, S.J., Kim, H.R., Shin, C.H., Choi, K.H., Joung, J.G., and Kim, H.H. (2016). Neurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3p. Biochim. Biophys. Acta. 1859: 599–611, https://doi.org/10.1016/j.bbagrm.2016.02.010.Search in Google Scholar PubMed

Lee, S., Karas, P.J., Hadley, C.C., Bayley, V.J.C., Khan, A.B., Jalali, A., Sweeney, A.D., Klisch, T.J., and Patel, A.J. (2019). The Role of Merlin/NF2 Loss in Meningioma Biology. Cancers (Basel) 11, https://doi.org/10.3390/cancers11111633.Search in Google Scholar PubMed PubMed Central

Li, B., Tao, B., Bai, H., Zhong, J., Wu, X., Shi, J., Sun, H., and Li, S. (2016). Papillary meningioma: an aggressive variant meningioma with clinical features and treatment: a retrospective study of 10 cases. Int. J. Neurosci. 126: 878–887, https://doi.org/10.3109/00207454.2015.1077833.Search in Google Scholar PubMed

Li, X.C., Hai, J.J., Tan, Y.J., Yue, Q.F., and Liu, L.J. (2019). MiR-218 suppresses metastasis and invasion of endometrial cancer via negatively regulating ADD2. Eur. Rev. Med. Pharmacol. Sci. 23: 1408–1417.Search in Google Scholar

Ludwig, N., Kim, Y.J., Mueller, S.C., Backes, C., Werner, T.V., Galata, V., Sartorius, E., Bohle, R.M., Keller, A., and Meese, E. (2015). Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs. Neuro. Oncol. 17: 1250–1260, https://doi.org/10.1093/neuonc/nov014.Search in Google Scholar PubMed PubMed Central

Mao, Y., Zhang, L., and Li, Y. (2019). circEIF4G2 modulates the malignant features of cervical cancer via the miR-218/HOXA1 pathway. Mol. Med. Rep. 19: 3714–3722.10.3892/mmr.2019.10032Search in Google Scholar PubMed PubMed Central

Marosi, C., Hassler, M., Roessler, K., Reni, M., Sant, M., Mazza, E., and Vecht, C. (2008). Meningioma. Crit. Rev. Oncol. Hematol. 67: 153–171, https://doi.org/10.1016/j.critrevonc.2008.01.010.Search in Google Scholar PubMed

Mawrin, C. and Perry, A. (2010). Pathological classification and molecular genetics of meningiomas. J. Neurooncol. 99: 379–391, https://doi.org/10.1007/s11060-010-0342-2.Search in Google Scholar PubMed

Mercado-Pimentel, M.E, Ly, N.H, Smith, B, Retana, C.C, Pizarro, J.K, Rolph, D.N Almario, R.D Wang, S and Jacob, A. (2018). ILK/AKT signaling regulates miR-21 expression in vestibular Schwannoma and Meningioma. Austin Journal of Medical Oncology 5.Search in Google Scholar

Mezue, W.C., Ohaegbulam, S.C., Ndubuisi, C.A., Chikani, M.C., and Achebe, D.S. (2012). Management of intracranial meningiomas in Enugu, Nigeria. Surg. Neurol. Int. 3: 110, https://doi.org/10.4103/2152-7806.101788.Search in Google Scholar PubMed PubMed Central

Murugaiyan, G., da, C.A.P., Ajay, A.K., Joller, N., Garo, L.P., Kumaradevan, S., Yosef, N., Vaidya, V.S., and Weiner, H.L. (2015). MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. J. Clin. Invest. 125: 1069–1080, https://doi.org/10.1172/jci74347.Search in Google Scholar PubMed PubMed Central

O’Brien, S.J., Carter, J.V., Burton, J.F., Oxford, B.G., Schmidt, M.N., Hallion, J.C., and Galandiuk, S. (2018). The role of the miR-200 family in epithelial-mesenchymal transition in colorectal cancer: a systematic review. Int. J. Cancer 142: 2501–2511, https://doi.org/10.1002/ijc.31282.Search in Google Scholar

Ostrom, Q.T., Gittleman, H., Liao, P., Vecchione-Koval, T., Wolinsky, Y., Kruchko, C., and Barnholtz-Sloan, J.S. (2017). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro. Oncol. 19: v1–1v88, https://doi.org/10.1093/neuonc/nox158.Search in Google Scholar

Ostrom, Q.T., Gittleman, H., Xu, J., Kromer, C., Wolinsky, Y., Kruchko, C., and Barnholtz-Sloan, J.S. (2016). CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro. Oncol. 18: v1–1v75, https://doi.org/10.1093/neuonc/now207.Search in Google Scholar

Peng, L., Fu, J., and Ming, Y. (2018). The miR-200 family: multiple effects on gliomas. Cancer Manag. Res. 10: 1987–1992, https://doi.org/10.2147/cmar.s160945.Search in Google Scholar

Pfeffer, S.R., Yang, C.H., and Pfeffer, L.M. (2015). The role of miR-21 in cancer. Drug. Dev. Res. 76: 270–277, https://doi.org/10.1002/ddr.21257.Search in Google Scholar

Proctor, D.T., Ramachandran, S., Lama, S., and Sutherland, G.R. (2018). Towards molecular classification of meningioma: evolving treatment and diagnostic paradigms. World Neurosurg. 119: 366–373, https://doi.org/10.1016/j.wneu.2018.08.019.Search in Google Scholar

Sahm, F., Schrimpf, D., Olar, A., Koelsche, C., Reuss, D., Bissel, J., Kratz, A., Capper, D., Schefzyk, S., Hielscher, T., et al. (2016). TERT Promoter Mutations and Risk of Recurrence in Meningioma. J. Natl. Cancer. Inst. 108, https://doi.org/10.1093/jnci/djv377.Search in Google Scholar

Sahm, F., Schrimpf, D., Stichel, D., DTW, J., Hielscher, T., Schefzyk, S., Okonechnikov, K., Koelsche, C., Reuss, D.E., Capper, D., et al. (2017). DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 18: 682–694, https://doi.org/10.1016/s1470-2045(17)30155-9.Search in Google Scholar

Sanson, M. and Kalamarides, M. (2017). Epigenetics: a new tool for meningioma management. Lancet. Oncol. 18: 569–570, https://doi.org/10.1016/s1470-2045(17)30153-5.Search in Google Scholar

Saydam, O., Shen, Y., Würdinger, T., Senol, O., Boke, E., James, M.F., Tannous, B.A., Stemmer-Rachamimov, A.O., Yi, M., Stephens, R.M., et al. (2009). Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/β-catenin signaling pathway. Mol. Cell. Biol. 29: 5923–5940, https://doi.org/10.1128/mcb.00332-09.Search in Google Scholar

Senol, O., Schaaij-Visser, T.B., Erkan, E.P., Dorfer, C., Lewandrowski, G., Pham, T.V., Piersma, S.R., Peerdeman, S.M., Ströbel, T., Tannous, B., et al. (2015). miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo. Oncogene 34: 1790–1798, https://doi.org/10.1038/onc.2014.120.Search in Google Scholar PubMed

Shaikh, N., Dixit, K., and Raizer, J. (2018). Recent advances in managing/understanding meningioma. F1000Res 7.10.12688/f1000research.13674.1Search in Google Scholar PubMed PubMed Central

Shalaby, T. and Grotzer, M.A. (2015). Tumor-associated csf micrornas for the prediction and evaluation of CNS malignancies. Int. J. Mol. Sci. 16: 29103–29119, https://doi.org/10.3390/ijms161226150.Search in Google Scholar PubMed PubMed Central

Shi, L., Jiang, D., Sun, G., Wan, Y., Zhang, S., Zeng, Y., Pan, T. and Wang, Z. (2012). miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J. Neurooncol. 110: 155–162, https://doi.org/10.1007/s11060-012-0951-z.Search in Google Scholar PubMed

Spiegl-Kreinecker, S., Lötsch, D., Neumayer, K., Kastler, L., Gojo, J., Pirker, C., Pichler, J., Weis, S., Kumar, R., Webersinke, G., et al. (2018). TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro. Oncol. 20: 1584–1593, https://doi.org/10.1093/neuonc/noy104.Search in Google Scholar PubMed PubMed Central

Sun, J., Tian, X., Zhang, J., Huang, Y., Lin, X., Chen, L., and Zhang, S. (2017). Regulation of human glioma cell apoptosis and invasion by miR-152-3p through targeting DNMT1 and regulating NF2 : MiR-152-3p regulate glioma cell apoptosis and invasion. J. Exp. Clin. Cancer Res. 36: 100, https://doi.org/10.1186/s13046-017-0567-4.Search in Google Scholar PubMed PubMed Central

Wang, M., Deng, X., Ying, Q., Jin, T., Li, M., and Liang, C. (2015). MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma. Biochem. Biophys. Res. Commun. 460: 354–361, https://doi.org/10.1016/j.bbrc.2015.03.038.Search in Google Scholar PubMed

Wang, Q., Li, P., Li, A., Jiang, W., Wang, H., Wang, J., and Xie, K. (2012). Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J. Exp. Clin. Cancer. Res. 31: 97, https://doi.org/10.1186/1756-9966-31-97.Search in Google Scholar PubMed PubMed Central

Wang, X., Wang, E., Cao, J., Xiong, F., Yang, Y., and Liu, H. (2017). MiR-145 inhibits the epithelial-to-mesenchymal transition via targeting ADAM19 in human glioblastoma. Oncotarget 8: 92545–92554, https://doi.org/10.18632/oncotarget.21442.Search in Google Scholar PubMed PubMed Central

Wang, Y., Wang, F., Wu, Y., Zuo, L., Zhang, S., Zhou, Q., Wei, W., Wang, Y., and Zhu, H. (2015). MicroRNA-126 attenuates palmitate-induced apoptosis by targeting TRAF7 in HUVECs. Mol. Cell. Biochem. 399: 123–130, https://doi.org/10.1007/s11010-014-2239-4.Search in Google Scholar PubMed

Wen, S.W., Zhang, Y.F., Li, Y., Liu, Z.X., Lv, H.L., Li, Z.H., Xu, Y.Z., Zhu, Y.G., and Tian, Z.Q. (2015). Characterization and effects of miR-21 expression in esophageal cancer. Genet. Mol. Res. 14: 8810–8818, https://doi.org/10.4238/2015.august.3.4.Search in Google Scholar PubMed

Werner, T.V., Hart, M., Nickels, R., Kim, Y.J., Menger, M.D., Bohle, R.M., Keller, A., Ludwig, N., and Meese, E. (2017). MiR-34a-3p alters proliferation and apoptosis of meningioma cells in vitro and is directly targeting SMAD4, FRAT1 and BCL2. Aging (Albany) 9: 932–954, https://doi.org/10.18632/aging.101201.Search in Google Scholar PubMed PubMed Central

Xu, L.G., Li, L.Y., and Shu, H.B. (2004). TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J. Biol. Chem. 279: 17278–17282, https://doi.org/10.1074/jbc.c400063200.Search in Google Scholar

Yang, C., Wang, C., Chen, X., Chen, S., Zhang, Y., Zhi, F., Wang, J., Li, L., Zhou, X., Li, N., et al. (2013). Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int. J. Cancer. 132: 116–127, https://doi.org/10.1002/ijc.27657.Search in Google Scholar PubMed

Yang, Y., Ding, L., Hu, Q., Xia, J., Sun, J., Wang, X., Xiong, H., Gurbani, D., Li, L., Liu, Y., et al. (2017). MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis. Mol. Cancer. 16: 141, https://doi.org/10.1186/s12943-017-0710-z.Search in Google Scholar PubMed PubMed Central

Youngblood, M.W., Duran, D., Montejo, J.D., Li, C., Omay, S.B., Özduman, K., Sheth, A.H., Zhao, A.Y., Tyrtova, E., Miyagishima, D.F., et al. (2019). Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J. Neurosurg., 1–10, https://doi.org/10.3171/2019.8.jns191266.Search in Google Scholar

Zeinali, T., Mansoori, B., Mohammadi, A., and Baradaran, B. (2019). Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis. Biomed. Pharmacother. 109: 195–207, https://doi.org/10.1016/j.biopha.2018.10.037.Search in Google Scholar PubMed

Zhi, F., Shao, N., Li, B., Xue, L., Deng, D., Xu, Y., Lan, Q., Peng, Y., and Yang, Y. (2016). A serum 6-miRNA panel as a novel non-invasive biomarker for meningioma. Sci. Rep. 6: 32067, https://doi.org/10.1038/srep-32067.Search in Google Scholar

Zhi, F., Zhou, G., Wang, S., Shi, Y., Peng, Y., Shao, N., Guan, W., Qu, H., Zhang, Y., Wang, Q., et al. (2013). A microRNA expression signature predicts meningioma recurrence. Int. J. Cancer. 132: 128–136, https://doi.org/10.1002/ijc.27658.Search in Google Scholar PubMed